ITCMDBv1
Clinical TrialID 5704

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023

Parkinson Disease

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5704
Evidence Id
5704
Core Evidence Id
5704
Source Clinical Trial Id
5688
Herb2 Clinical Trial Id
HBCT005688
Nct Id
NCT02233023
Title
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
Status
Completed
Phase
Phase 4
Study Result
No
Study Condition
Parkinson Disease
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Pramipexole|DRUG: Bromocriptine and other dopamine agonists
Intervention Allocation
Non_Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Child, Adult, Older_Adult
Enrollment
705
Outcome Measure
Incidence of drug related signs of retinal degeneration, based on the evaluation of assessors blind to the treatment allocation, up to 8 months
Sponsor Collaborator
Boehringer Ingelheim
Funded By
INDUSTRY
Location
Other Id
248.342
Start Date
1998-06
Primary Completion Date
2000-06
Completion Date
First Posted
2014-09-08
Results First Posted
Last Update Posted
2014-09-08
Study Document
Study Url
https://clinicaltrials.gov/study/NCT02233023
Title Cn
Title En
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
Bilingual Status
semi_complete